Welcome to our dedicated page for MCURF news (Ticker: MCURF), a resource for investors and traders seeking the latest updates and insights on MCURF stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect MCURF's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of MCURF's position in the market.
MINDCURE has launched its original line of nootropic and adaptogen supplements, including Lion's Mane Focus, Reishi Energy, Turkey Tail Immunity, and Teen. Available for purchase on their website, shipping starts on February 23, 2021. This launch signifies a key milestone in MINDCURE's product sales strategy aimed at enhancing mental hygiene and overall wellness. The products are made from all-natural ingredients and are designed to boost mental performance and support immune health, with particular attention to teen safety standards as per California's Proposition 65.
Mind Cure Health (CSE: MCUR, OTCQB: MCURF) responded to promotional activities related to its shares, sparked by articles from the National Inflation Association. The Company was unaware of these articles until notified by OTC Markets on February 11, 2021. Mind Cure attributes a recent surge in trading volume to a C$23 million bought deal offering announced on February 10. The Company has also engaged Sandstone Media Inc. for marketing services at a cost of US$1,960,632. No insider trading was reported within the last 90 days, except for a small purchase and sale by key executives.
Mind Cure Health Inc. (CSE: MCUR) has engaged Dr. Dan Engle as Primary Investigator Consultant for its research into psychedelic compounds for treating traumatic brain injury (TBI). Dr. Engle, a board-certified psychiatrist and neurologist, brings a wealth of experience from his clinical practice focused on functional medicine and neuro-cognitive restoration. The company identifies TBI as a priority due to its rising prevalence, with TBI-related emergency visits increasing by 53% from 2006 to 2014 in North America. Mind Cure aims to advance its TBI research from pre-clinical to clinical stages.
MINDCURE has successfully completed beta testing of its PsyCollage bioinformatics platform, reaching its Q1 milestone. This platform enhances drug lead optimization and the discovery of target receptors in psychedelic research. PsyCollage has identified key indications, including neuropathic pain and migraines, and aims to facilitate strategic partnerships. Additionally, 800,000 stock options were granted to employees at a price of $0.65 per share. The company is committed to innovating mental health care and addressing the urgent need for effective treatments.